AVANOS MEDICAL (NYSE:AVNS) Releases FY 2025 Earnings Guidance

Key Points

• Avanos Medical has provided FY 2025 earnings guidance with EPS expected to be between 0.750-0.950, slightly below the consensus estimate of 0.850, and revenue guidance set at $665 million-$685 million compared to the consensus of $672 million.
• Following the earnings guidance announcement, Avanos Medical's stock fell by 17.1%, closing at $9.33, significantly below its fifty-day moving average of $12.09.
• Hedge funds and institutional investors have increased their stakes in Avanos Medical, with 95.17% of the stock currently owned by such entities, indicating strong institutional interest.

AVANOS MEDICAL (NYSE:AVNS - Get Free Report) issued an update on its FY 2025 earnings guidance on Tuesday morning. The company provided earnings per share guidance of 0.750-0.950 for the period, compared to the consensus earnings per share estimate of 0.850. The company issued revenue guidance of $665.0 million-$685.0 million, compared to the consensus revenue estimate of $672.0 million.

AVANOS MEDICAL Stock Up 0.3%

NYSE:AVNS traded up $0.04 on Friday, reaching $10.78. The stock had a trading volume of 787,704 shares, compared to its average volume of 599,158. The company has a current ratio of 2.64, a quick ratio of 1.56 and a debt-to-equity ratio of 0.12. The company has a 50-day moving average of $11.92 and a 200 day moving average of $13.39. The stock has a market cap of $499.96 million, a P/E ratio of -1.07 and a beta of 1.12. AVANOS MEDICAL has a 12-month low of $9.30 and a 12-month high of $25.36.

AVANOS MEDICAL (NYSE:AVNS - Get Free Report) last posted its quarterly earnings data on Tuesday, August 5th. The company reported $0.17 earnings per share for the quarter, missing analysts' consensus estimates of $0.18 by ($0.01). The firm had revenue of $175.00 million during the quarter, compared to analysts' expectations of $165.50 million. AVANOS MEDICAL had a negative net margin of 66.89% and a positive return on equity of 6.16%. During the same period in the previous year, the company earned $0.34 earnings per share. On average, research analysts predict that AVANOS MEDICAL will post 1.32 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Separately, Wall Street Zen cut shares of AVANOS MEDICAL from a "strong-buy" rating to a "buy" rating in a research report on Saturday.

Hedge Funds Weigh In On AVANOS MEDICAL

Hedge funds have recently bought and sold shares of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in AVANOS MEDICAL by 4.3% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 26,955 shares of the company's stock worth $386,000 after purchasing an additional 1,121 shares in the last quarter. Creative Planning grew its stake in AVANOS MEDICAL by 205.8% in the second quarter. Creative Planning now owns 35,281 shares of the company's stock worth $432,000 after purchasing an additional 23,745 shares in the last quarter. Intech Investment Management LLC grew its stake in AVANOS MEDICAL by 154.3% in the first quarter. Intech Investment Management LLC now owns 124,061 shares of the company's stock worth $1,778,000 after purchasing an additional 75,279 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in AVANOS MEDICAL by 17.1% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 140,810 shares of the company's stock worth $2,018,000 after purchasing an additional 20,541 shares in the last quarter. Finally, Empowered Funds LLC grew its stake in AVANOS MEDICAL by 5.4% in the first quarter. Empowered Funds LLC now owns 162,182 shares of the company's stock worth $2,324,000 after purchasing an additional 8,348 shares in the last quarter. 95.17% of the stock is currently owned by institutional investors and hedge funds.

About AVANOS MEDICAL

Avanos Medical, Inc, a medical technology company, offers medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions.